Youcare Pharmaceutical Group Co., Ltd. (SHA:688658)
China · Delayed Price · Currency is CNY 18.77
-0.75 (-3.84%)
Apr 21, 2026, 3:00 PM CST
SHA:688658 Income Statement
Financials in millions CNY. Fiscal year is January - December.
Millions CNY. Fiscal year is Jan - Dec.
Fiscal Year | FY 2025 | FY 2024 | FY 2023 | FY 2022 | FY 2021 |
|---|---|---|---|---|---|
Period Ending | Dec '25 Dec 31, 2025 | Dec '24 Dec 31, 2024 | Dec '23 Dec 31, 2023 | Dec '22 Dec 31, 2022 | Dec '21 Dec 31, 2021 |
Operating Revenue | 2,440 | 3,767 | 4,183 | 4,521 | 4,942 |
Other Revenue | 6.3 | 13.47 | 13.63 | 20.97 | 23.84 |
| 2,446 | 3,781 | 4,196 | 4,542 | 4,966 | |
Revenue Growth (YoY) | -35.30% | -9.90% | -7.61% | -8.53% | 14.45% |
Cost of Revenue | 1,258 | 1,640 | 1,622 | 1,669 | 1,556 |
Gross Profit | 1,188 | 2,141 | 2,574 | 2,873 | 3,410 |
Selling, General & Admin | 956.99 | 1,526 | 1,983 | 2,213 | 2,552 |
Research & Development | 441.21 | 374.31 | 351.88 | 344.42 | 200.03 |
Other Operating Expenses | 29.54 | 32.45 | 38.75 | 54.32 | 63.74 |
Operating Expenses | 1,424 | 1,927 | 2,360 | 2,633 | 2,836 |
Operating Income | -235.77 | 213.69 | 214.88 | 240 | 574.2 |
Interest Expense | -21.65 | -22.4 | -13.21 | -4.7 | -3.47 |
Interest & Investment Income | 12.32 | 18.06 | 23.4 | 28.27 | 35.18 |
Currency Exchange Gain (Loss) | -0.04 | 0.94 | 1.33 | 10.19 | 6.57 |
Other Non Operating Income (Expenses) | -0.45 | -45.75 | -1.24 | -1.08 | -1.18 |
EBT Excluding Unusual Items | -245.6 | 164.55 | 225.15 | 272.68 | 611.3 |
Gain (Loss) on Sale of Investments | 6.04 | 2.34 | -0.69 | 2.89 | - |
Gain (Loss) on Sale of Assets | -1.54 | -2.3 | -2.77 | -9.73 | -5.27 |
Asset Writedown | -16.03 | -33.57 | -21.78 | - | -19.17 |
Other Unusual Items | 20.07 | 21.34 | 23.36 | 83.68 | 42.41 |
Pretax Income | -237.05 | 152.36 | 223.27 | 349.53 | 629.27 |
Income Tax Expense | 37.76 | 31.11 | 35.77 | 10.62 | 85.55 |
Earnings From Continuing Operations | -274.82 | 121.25 | 187.49 | 338.91 | 543.72 |
Minority Interest in Earnings | 12.43 | 2.47 | -2.7 | -3.72 | 1.59 |
Net Income | -262.39 | 123.72 | 184.8 | 335.18 | 545.32 |
Net Income to Common | -262.39 | 123.72 | 184.8 | 335.18 | 545.32 |
Net Income Growth | - | -33.05% | -44.87% | -38.53% | 23.34% |
Shares Outstanding (Basic) | 445 | 442 | 451 | 453 | 451 |
Shares Outstanding (Diluted) | 445 | 442 | 451 | 453 | 451 |
Shares Change (YoY) | 0.65% | -1.97% | -0.49% | 0.51% | 25.37% |
EPS (Basic) | -0.59 | 0.28 | 0.41 | 0.74 | 1.21 |
EPS (Diluted) | -0.59 | 0.28 | 0.41 | 0.74 | 1.21 |
EPS Growth | - | -31.71% | -44.59% | -38.84% | -1.63% |
Free Cash Flow | 205.21 | 79.64 | 288.01 | -669.13 | 314.75 |
Free Cash Flow Per Share | 0.46 | 0.18 | 0.64 | -1.48 | 0.70 |
Dividend Per Share | - | - | 0.200 | 1.100 | 0.680 |
Dividend Growth | - | - | -81.82% | 61.77% | 51.11% |
Gross Margin | 48.58% | 56.62% | 61.35% | 63.25% | 68.67% |
Operating Margin | -9.64% | 5.65% | 5.12% | 5.28% | 11.56% |
Profit Margin | -10.73% | 3.27% | 4.40% | 7.38% | 10.98% |
Free Cash Flow Margin | 8.39% | 2.11% | 6.86% | -14.73% | 6.34% |
EBITDA | -38.5 | 413.13 | 383.01 | 394.15 | 709.47 |
EBITDA Margin | -1.57% | 10.93% | 9.13% | 8.68% | 14.29% |
D&A For EBITDA | 197.27 | 199.44 | 168.13 | 154.15 | 135.28 |
EBIT | -235.77 | 213.69 | 214.88 | 240 | 574.2 |
EBIT Margin | -9.64% | 5.65% | 5.12% | 5.28% | 11.56% |
Effective Tax Rate | - | 20.42% | 16.02% | 3.04% | 13.59% |
Revenue as Reported | 2,446 | 3,781 | 4,196 | 4,542 | 4,966 |
Advertising Expenses | 4.49 | 4.75 | 14.7 | 18.36 | - |
Updated Dec 31, 2025. Source: S&P Global Market Intelligence. Standard template. Financial Sources.